Progression of prostate cancer is associated with an increase in de novo fatty acid synthesis which is independent from systemic lipid levels [24] with an increase in key enzymes in the lipogenic pathway, including fatty acid synthase (FASN) in metastatic CRPC. Here, FASN is linked to prostate carcinoma.